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Summary: Data from 7045 subjects were examined. The main groups consisted of the following in- and outpatients:
1414 neonates, 2554 children and adolescents (1336 males, 1218 females), 1209 women directly postpartum, 786
non-pregnant women and 1090 men aged between 18 and 100 years of age. Unless otherwise stated, persons were
under medical observation or therapy.
The results were obtained over a three-year period using an in-house immunolurninometric assay specific for
apolipoprotein(a) using two polyclonal antibodies and a single lot of reagents to allow for comparability of results.
Girls aged between 10 and 12 years of age had significantly higher serum lipoprotein(a) (median 124 mg/1) levels
than boys (median 88 mg/1) of the same age (p < 0.05 - Mann-Wliitney U-test). Post-pubertal lipoprotein(a) con-
centrations were not significantly different from pre-pubertal levels. Between the ages of 0-9 and 13-17 years
there were no statistically significant sex-linked differences in serum lipoprotein(a).
In adults, lipoprotein(a) serum levels were significantly higher in women (median 163 mg/1) aged between 50 and
59 years, when compared with men (median 128 mg/1) of the same age group (p = 0.05 — Kruskal-Wallis one way
ANOVA followed by the Nemenyi test).
There was no significant difference in serum lipoprotein(a) concentrations between healthy women (median 91
mg/1), women direct postpartum (median 116 mg/1) and in-patient women (median 117 mg/1) aged between 18 and
41 years of age (p = 0.11—0.96). There was no correlation between maternal lipoprotein(a) and birth weight in
mature newborns (r = -0.028-0.085).
The results may indicate a direct influence of gonadotropins at puberty and during the menopause which cause an
increase in serum lipoprotein(a) concentrations.
Introduction fact is that large numbers of observations within a group
, ,
 f . . , , . are needed to obtain a stable median lipoprotein(a) con-Although hpoprotem(a) is an accepted additional and in- , ..
r - , n n i * , · centration.dependent risk factor for early onset atherosclerotic
changes (1-4), relatively little is known about factors The results presented in this article have been derived
influencing its concentration in blood. Conflicting re- from over three years of observations using a single lot
ports about changes in lipoprotein(a) concentrations in of reagents, thus excluding variation due to methodol-
serum in response to hormonal activity may be due to ogy and changing reagents and calibration materials,
several conditions, including the size of the group j^ hypothesis that lipoprotein(a) concentrations may
studied (5, 6), the time-period of observation (6, 7), the
 be affected by gonadotropins has been examined using
method used for quantitation (8), and the statistics used observations made in this hospital as well as from those
for comparison (9). published in the literature, where the effects of preg-
The non-OniHian distribution of lipoprotein(a) concen- nancy (7> »O"14). pituitary hormones (15, 16) and dif-
trations, together with the wide range of concentrations ferent druSs (»· I7~19) are weU documented,
found in serum, allow only non-parametric statistics to
be used. In addition, the median value for lipoprotein(a) Subjects and Methods
lies in a concentration range where relative few results
 ooor
. Data from a total of 7045 subjects (3159 males, 3886 females)
are to be found, in contrast to the mean value m a nor-
 were processed in this study and included 2554 children and ado-
mally distributed population. The consequence of this lescents (1336 males, 1218 females), 1209 mothers directly post-
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Fig. l Median lipoprotein(a) concentrations in subjects at birth and aged between
2 weeks and 100 years of age. Data from 3159 males and 3886 females M were used.
partum and 786 non-pregnant women aged between 18 and 96
years of age. In addition, data from 1090 males aged between 18
and 100 years of age and 1414 newborns were used for compari-
son. Lipoprotein(a) was measured with an in-house immunolumi-
nometric assay using two polyclonal antibodies directed against
apolipoprotein(a). The method has been published elsewhere (20)
and has been used for extensive studies (21—23) as well as for
routine puiposes. A single lot of reagents has been used throughout
the study and thus allows for comparison of results over the whole
observation period.
Stat is t ics
Non-parametric statistics have been used throughout. The median
has been used as the measure of central tendency, relevant percen-
tiles as measure of dispersion. For comparison of two groups, the
Mann-Whitney U-test was used for independent samples; for com-
parison of several groups, the Kniskal-Wallis one way analysis of
variance was followed by the Nemenyi test to check for differences
between groups.
Results
Figure 1 shows the distribution of lipoprotein(a) values
throughout life in 7045 subjects. Table la shows the
same for children aged 2 weeks to 17 years. Table Ib
also shows the detailed data for women aged 18—59
years, who have been depicted in figure 1. Table 2 shows
the correlation between maternal serum lipoprotein(a)
and birth weight for all mother child pairs, and for
mother child pairs where maternal lipoprotein(a) was in
excess of 300 mg/1 (300-3150 mg/1). Data are sorted
according to sex of the child.
From figure 1 and table 1 a it can be clearly seen that
lipoprotein(a) peaks occur in females at puberty (tab.
1 a) and after the menopause (fig. 1). In girls aged be-
tween 10 and 12 years of age, lipoprotein(a) concentra-
tions are significantly higher (p < 0.05) than in boys of
the corresponding ages. Between the ages of 0 and 9,
and 13 and 17 years of age, no statistically significant
sex-linked difference in lipoprotein(a) levels was found.
In adults, lipoprotein(a) was significantly higher in
women aged 50 to 59 years of age (p = 0.05) than in
men of the corresponding age group.
Table Ib shows the lipoprotein values in age matched
females, for healthy hospital staff attending a routine
check-up, for non-selected in-patient women and for
women directly after the birth of a child. Although the
median values are different, these are not significant
(healthy women vs hospitalised women p = 0.45, heal-
thy women vs postpartal women p = 0.11, hospitalised
Tab. la Median lipoprotein(a) concentrations in serum of chil-
dren aged 2 weeks to 17 years of age divided into age and sex.
Median concentrations are given in mg/1.
Age
group
(years)
2 weeks -1 year
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
1 — 5 years
6-10
11-17
Male children
Lipo-
protein(a)
(mg/1)
38.9
30.8
45.5
53.0
61.5
59.0
80.2
75.7
69.5
76.7
97.4
88.2
79.4
74.1
103
117
74.3
66.9
47.5
78.1
84.3
n
167
97
97
76
83
81
104
76
64
62
86
66
60
69
51
34
40
19
434
396
339
Female children
Lipo-
protein(a)
(mg/1)
36.4
41.7
44.7
44.7
68.6
80.5
79.8
92.7
76.3
73.8
118
146
93.0
83.9
73.0
102
95.0
101
54.0
81.4
95.8
n
161
96
80
55
56
71
57
59
82
73
76
60
71
60
53
44
39
30
358
342
357
All 66.5 1336 67.6 1218
The corresponding mean values for all subjects was 175 mg/1 (boys
167 mg/1, girls 183 mg/1) showing the extreme skewness of the
data (mean: median = 2.61). The median value stabilises first after
the number of subjects in a group exceeds at least 100 persons,
and so groups from children aged between 1 and 17 years were
constructed as in the lower part of the table. Only the group values
were used in figure 1.
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Tab. Ib Lipoprotein(a) data for healthy, postpartuni and sick females aged 18-59 years of age.
Median concentrations are given in mg/l.
Age group
(years)
18-29
30-39
40-49
50-59
Healthy
Lipoprotein(a)
(mg/1)
87.0
87.5
97.0
146
n
104
112
55
93
Postpartum
Lipoprotein(a) n
(mg/1)
111 876
121 320
α
Sick
Lipoprotein(a)
(mg/1)
79.5
121
130
190
η
56
54
56
110
α
 As there were only 13 mothers over 40 years of age, these were not included in the table.
The median lipoprotein(a) concentration of this group was 184 mg/1.
women vs post partal women ρ = 0.96), thus allowing
all women of a given age-group to be included in one
group in figure 1.
Table 2 shows that there was no correlation between
maternal serum lipoprotein(a) and birth weight in full
term babies (38th—43rd week of pregnancy). This was
true before and after logarithmic transformation of lipo-
protein(a) concentrations. The correlation between post-
partal maternal and neonatal lipoprotein(a) concentra-
tions after logarithmic transformation was r = 0.592
(n = 1209).
Relevant assay data, represented by the mean and inter-
assay coefficient of variation (in parentheses) for four
control sera were as follows:
Serum A: mean 105 mg/1 (5.66%) n = 172,
Serum B: mean 377 mg/1 (5.55%) n = 62,
Serum C: mean 808 mg/1 (4.30%)
[declared content 800 mg/1] n = 31 and
Serum D: mean 37.4 mg/1 (7.86%) n = 61.
Discussion
Many conflicting reports have been published on the be-
haviour of lipids and lipoproteins during puberty (24),
Tab. 2 Correlation between maternal lipoprotein(a) and birth
weight according to sex of the baby and lipoprotein(a) concentra-
tion of the mother at birth. Only full-term newborns are included.
Linear
correlation
Log
correlation
Lipoprotein(a)
less than 300 mg/l
Male offspring
Female offspring
420
367
-0.014
0.007
0.020
-0.028
Lipoprotein(a)
above 300 mg/l
Male offspring
Female offspring
137
150
-0.018
0.085
0.035
0.033
The data for the linear correlation was calculated from the birth
weight (x) and the lipoprotein(a) concentration in mg/l (y).
The data for the logarithmic correlation was calculated from the
birth weight (x) and the decadian logarithm of the lipoprotein(a)
concentration (y).
pregnancy (7, 10-14), under the influence of drugs (19,
25), oral contraceptives (17) and hormones (19, 26, 27),
including gonadotropins (15, 16). Results from animal
studies (28) cannot be compared directly with results
from humans (5) without due consideration of animal
physiology. Other results come from studies in which
the number of subjects is too small for comparison (5),
even when 'statistically significant' differences have
been found.
Reports of behavour of lipoprotein(a) during pregnancy
are also conflicting, some authors not seeing an increase
(10, 12, 29), others reporting significant increases (11,
13, 14). In a study of smoking and non-smoking preg-
nant women, van Wersch et al. (30) showed that the lipo-
protein(a) levels in non-smoking pregnant women were
on average twice as high as in women who smoked, the
latter having the same concentrations as non-pregnant
women.
Association of high levels of lipoprotein(a) in maternal
serum have been associated with severe pre-eclamptic
pregnancy (31) and foetal growth retardation due to in-
sufficient placental circulation (32). Peripartal reduc-
tions in total cholesterol, high density lipoprotein chol-
esterol and apolipoprotein A-I, when compared with
levels in the 35th week of pregnancy have also been
published (5), as have observations in reduction of tria-
cylglycerols, cholesterol and apolipoprotein B measured
6 weeks postpartum, when compared with levels in the
35th and 36th weeks of pregnancy (10, 12). Chiang and
co-workers (12), however reported no change in apoli-
poprotein A-I during pregnancy.
In a study covering 232 women during pregnancy (114
Caucasians, 118 Africans/Afro-Caribbeans), Koukou et
al. (6) found lower levels of total cholesterol, low-den-
sity lipoprotein cholesterol, triacylglycerols and apolipo-
protein B, but higher levels of high-density lipoprotein
cholesterol and lipoprotein(a) in Africans/Afro-Caribbe-
ans, when compared with Caucasians. The differences
were not due to weight, age, parity or post-load plasma
glucose levels.
Munoz et al. (33) have observed decreased apolipoprot-
ein A and triacylglycerols in pregnancies with intra-uter-
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ine growth retardation. Rheological changes were seen
in this group of patients which were due to the inhibition
of fibrinolysis by increased levels ofapolipoprotein B.
Zechner and co-workers (7) reported a steady increase
of lipoprotein(a) in pregnant women up until the 19th
week, where the values were on average 2.8 times
higher than before the pregnancy, after which values fell
to pre-pregnant values at birth. Apolipoprotein B and
total cholesterol increased during pregnancy, the time
courses being independent ofthat of lipoprotein(a).
Soma et al. (11) reported that steroid sex-hormones were
capable of reducing lipoprotein(a) concentrations in
postmenopausal women, and after cessation of hor-
mone-substitution, that the levels returned to pre-treat-
ment concentrations. In men undergoing orchidectomy
for prostatic cancer, the same workers observed in-
creases in lipoprotein(a) of 20%, whereas treatment with
oestrogens resulted in a reduction of lipoprotein(a) by
50%. Similar results have been reported by Habiba et
al. (34). In hormone replacement therapy using a combi-
nation of oestriol, oestrone, oestradiol and norethister-
one a reduction of serum lipoprotein(a) concentrations
and protein-S activity was seen over the observation
period of one year.
Radwanska (18) has presented data in a review article
which implies different effects of sex-steroids and syn-
thetic oestrogens on lipoprotein levels, and that these
effects differ with age, sex, pregnancy, body weight and
smoking habits. Moreover, the route of application and
whether the hormones are endogenous or exogenous ap-
pear to influence lipoprotein levels, thus complicating
the picture. Similar results have recently been published
by Stone (19).
Results from the Burgos study on high density lipopro-
teins during the second decade of life (24) noted in-
creases in high density lipoprotein phospholipids in girls
after puberty, but not in boys. In another Spanish study
girls and boys between 13 — 14 years of age from Alcoy
(35), 38% were classified as having elevated lipopro-
tein(a) and were classified as 'at-risk'. Further compari-
sons with values obtained in our observations were not
possible, due to the use of parametric statistics.
In the Atherosclerosis Risk in Communities (ARIC)
study (36) carried out on men and women aged between
45-64 years of age, women, both black and white, had
higher lipoprotein(a) levels than men. In addition, in
postmenopausal women on hormone replacement ther-
apy lipoprotein(a) as well as apolipoprotein B and low
density lipoprotein cholesterol levels were lower than in
non-replacement women.
Stevenson et al. (37) conclude from a study on the influ-
ence of age and menopause on serum lipids and lipopro-
teins, that 'the menopause is associated with potentially
adverse changes in lipids and lipoproteins, independent
of any effects of aging. These changes may in part ex-
plain the increased incidence of coronary heart disease
seen in postmenopausal women'.
The observations made by different groups must first be
classified exactly before attempting to extract data for
support of the hypothesis that gonadotropins directly in-
fluence levels of lipoprotein(a) in serum.
The results from the Burgos study (24) show that
changes in the phospholipid content of high-density li-
poproteins only occured in girls during and after pu-
berty. In our study, significant increases in serum lipo-
protein^) occured in girls during puberty, but de-
creased afterwards.
In postmenopausal women several groups (34—37)
have reported changes in lipid and lipoprotein profiles,
including an increase in lipoprotein(a), which can be
reversed by sex-steroid therapy. The review of Rad-
wanska (18) has shown that certain sex-steroids are
capable of changing the lipid and lipoprotein levels,
including the reduction of lipoprotein(a). From our
data, there is a significant increase in lipoprotein(a)
after the menopause, which is seen until the end of
the eighth decade of life.
The Austrian group of Zechner et al. (7) observed in-
creases in lipoprotein(a) during the first half of preg-
nancy, values then returning to normal at birth. Other
cholesterol fractions increased well into the second half
of pregnancy. The first half of pregnancy is 'governed'
by gonadotropins, the second by sex-steroids.
The above results show that gonadotropins increase lipo-
protein(a), as seen in the results from pubertal girls, but
not boys, and in postmenopausal women, but not in age-
matched men. Reduction of post-menopausal gonadotro-
pins by steroid sex-hormones results in a fall in serum
lipoprotein(a). The different time courses of different
lipids and lipoprotein fractions during pregnancy and af-
ter the menopause point to an independent pathway for
lipöprotein(a), and which may very well support the ob-
servations and theory of Stevenson et al. (37).
The peak of lipoprotein(a) levels at puberty in girls may
reflect the gonadotropin activity, the reduction after pub-
erty to the interaction between gonadotropins and sex-
steroids during the menstrual cycle.
The results from the postmenopausal women can only
support a hormone replacement therapy to reduce the
increased risk of cardiovascular problems in this
group.
From our results and those from other groups we may
infer that an increase in gonadotropins may contribute to
an adverse effect, namely an increase, in lipoprotein(a),
which may be reversed by sex-hormone steroid substitu-
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tion. From the results from oestrogen therapy on orchi-
dectomised men (11), the lowering of lipoprotein(a) is
not sex-linked. Further indirect evidence for a link be-
tween gonadotropins and lipoprotein(a) may be seen in
the fact that long-term hormone replacement therapy in
postmenopausal women reduces the incidence of myo-
cardial infarction by up to 50% during the therapeutical
period (38). After cessation of therapy there is less con-
sensus as to whether this protective effect is retained.
From the data in table Ib there is no support to the claim
that high maternal lipoprotein(a) levels were correlated
with lower birth weight due to placental insufficiency
(31, 32) at least in full-term babies.
An interesting postulation for future therapy is whether
steroids with an aromatic -ring may be 'designed' to
reduce lipoprotein(a), without having the unwanted side
effects, at least in men, of feminisation.
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